April 2022 "SAN DIEGO, April 12, 2022 — Crinetics Pharmaceuticals , Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization All of the shares to be sold in the offering are to be sold by Crinetics. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions

December 2021 Crinetics Pharmaceuticals announced the formation of an independently operated new company nonpeptide radiopharmaceuticals for the treatment of a broad range of oncology indications "– Co-founded by Crinetics Company Launches with $30M in Initial Financing Provided by 5AM and Frazier – Pipeline is Built from Crinetics to Collaborate on Multiple Additional targets SAN DIEGO, October 18, 2021 — Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization

March 2022 Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief Commercial Officer "SAN DIEGO – March 1, 2022 – Crinetics Pharmaceuticals , Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization

Prior to Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences Struthers co-founded and serves as board chair at Radionetics Oncology, a pharmaceutical company focused Scott Struthers on the web LinkedIn Google Scholar Crinetics Radionetics Dr.

Khaled Abdelrahman graduated in 2006 with a BSc in Pharmaceutical Sciences from Alexandria University He is also a Registered Pharmacist in Canada and held two of the most prestigious Clinician Postdoctoral

Khaled Abdelrahman graduated in 2006 with a BSc in Pharmaceutical Sciences from Alexandria University He is also a Registered Pharmacist in Canada and held two of the most prestigious Clinician Postdoctoral